Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>ResMed's fourth quarter fiscal year 2025 results present a balanced outlook for potential investors, highlighting a mix of strong financial performance and strategic challenges.</li><li>The company reported a 10% year-over-year increase in headline revenue and a 230 basis point expansion in gross margin, indicating strong operational execution and cost management.</li><li>This growth was fueled by robust demand across its product and ReSupply portfolios, with notable performance in both the U.S., Canada, Latin America, and internationally.</li></ul>

ResMed's fourth quarter fiscal year 2025 results present a balanced outlook for potential investors, highlighting a mix of strong financial performance and strategic challenges.The company reported a 10% year-over-year increase in headline revenue and a 230 basis point expansion in gross margin, indicating strong operational execution and cost management.This growth was fueled by robust demand across its product and ReSupply portfolios, with notable performance in both the U.S., Canada, Latin America, and internationally.

ResMed: Accelerating Global Expansion With Strong Growth in Europe & China!

Derivatives and Quantitative Strategist

Gaudenz Schneider

Fisher & Paykel Healthcare Cor / Equity Bottom-Up

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Healthcare (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> Price-Ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: The long position is supported by higher growth aligning well with the statistical analysis. The trade faces some event risk due to an upcoming earnings announcement.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Healthcare (FPH AU) vs. ResMed (RMD AU) Price-Ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: The long position is supported by higher growth aligning well with the statistical analysis. The trade faces some event risk due to an upcoming earnings announcement.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

<ul><li>ResMed Inc.'s Q3 Fiscal Year 2025 results reflected both robust performance and strategic plans poised for long term growth, giving investors a mixed but intriguing picture of the company's current standing and future potential.</li><li>The company reported strong financial results, with an 11% increase in non-GAAP net income and a 13% boost in diluted earnings per share, reaching $2.37.</li><li>Revenue rose by 8% on a headline basis and 9% in constant currency terms, reflecting comprehensive growth across products and markets.</li></ul>

ResMed Inc.'s Q3 Fiscal Year 2025 results reflected both robust performance and strategic plans poised for long term growth, giving investors a mixed but intriguing picture of the company's current standing and future potential.The company reported strong financial results, with an 11% increase in non-GAAP net income and a 13% boost in diluted earnings per share, reaching $2.37.Revenue rose by 8% on a headline basis and 9% in constant currency terms, reflecting comprehensive growth across products and markets.

ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position!

<ul><li>ResMed Inc.'s second quarter fiscal year 2025 earnings presentation highlights several notable financial and operational results, alongside key strategic initiatives.</li><li>From a performance standpoint, the company reported a global revenue increase of 10%, reaching $1.28 billion.</li><li>This growth spanned ResMed's key business sectors, including device sales, which rose by 11%, and masks and accessories, which grew by 11% as well.</li></ul>

ResMed Inc.'s second quarter fiscal year 2025 earnings presentation highlights several notable financial and operational results, alongside key strategic initiatives.From a performance standpoint, the company reported a global revenue increase of 10%, reaching $1.28 billion.This growth spanned ResMed's key business sectors, including device sales, which rose by 11%, and masks and accessories, which grew by 11% as well.

ResMed: How Sleep Apnea Awareness is Expanding Global Market Potential! - Major Drivers

<ul><li>ResMed's Q1 Fiscal Year 2025 earnings report presented a strong start to the year, showing an impressive trajectory in revenue growth, profitability, and operational efficiency.</li><li>The company's focused growth across its core business segments has yielded a reported 11% revenue increase, attributed to robust demand for sleep health, breathing devices, masks, accessories, and residential care software offerings, spanning across global markets.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

ResMed's Q1 Fiscal Year 2025 earnings report presented a strong start to the year, showing an impressive trajectory in revenue growth, profitability, and operational efficiency.The company's focused growth across its core business segments has yielded a reported 11% revenue increase, attributed to robust demand for sleep health, breathing devices, masks, accessories, and residential care software offerings, spanning across global markets.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

ResMed Inc.: Expanding Patient Access and Engagement with Technology To Catalyze Growth! - Major Drivers

United States

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ResMed (RMD UN)

ResMed: Accelerating Global Expansion With Strong Growth in Europe & China!

ResMed's fourth quarter fiscal year 2025 results present a balanced outlook for potential investors, highlighting a mix of strong financial...

Baptista Research

Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.

Gaudenz Schneider

ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position!

ResMed Inc.'s Q3 Fiscal Year 2025 results reflected both robust performance and strategic plans poised for long term growth, giving investors a...

Baptista Research

ResMed: How Sleep Apnea Awareness is Expanding Global Market Potential! - Major Drivers

ResMed Inc.'s second quarter fiscal year 2025 earnings presentation highlights several notable financial and operational results, alongside key...

Baptista Research

ResMed Inc.: Expanding Patient Access and Engagement with Technology To Catalyze Growth! - Major Drivers

ResMed's Q1 Fiscal Year 2025 earnings report presented a strong start to the year, showing an impressive trajectory in revenue growth,...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

ResMed: Accelerating Global Expansion With Strong Growth in Europe & China!

ResMed's fourth quarter fiscal year 2025 results present a balanced outlook for potential investors, highlighting a mix of strong financial...

Baptista Research

Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare

​FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.

Gaudenz Schneider

ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position!

ResMed Inc.'s Q3 Fiscal Year 2025 results reflected both robust performance and strategic plans poised for long term growth, giving investors a...

Baptista Research

ResMed: How Sleep Apnea Awareness is Expanding Global Market Potential! - Major Drivers

ResMed Inc.'s second quarter fiscal year 2025 earnings presentation highlights several notable financial and operational results, alongside key...

Baptista Research

ResMed Inc.: Expanding Patient Access and Engagement with Technology To Catalyze Growth! - Major Drivers

ResMed's Q1 Fiscal Year 2025 earnings report presented a strong start to the year, showing an impressive trajectory in revenue growth,...

Baptista Research

FPH AU vs. RMD AU price-ratio deviates from average, offering potential value opportunity for quantitative traders with risk management protocols.